[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Download PDF
Figure.
Fluorescein angiography before and after daclizumab treatment for patient 6. A and B, Late-phase fluorescein angiography frames of right and left eyes while patient is taking mycophenolate mofetil and cyclosporin A and immediately before starting daclizumab treatment. Note the temporal arcade vasculitis. C and D, After 2 years of daclizumab treatment, there is no vasculitis in the late frames of the angiogram.

Fluorescein angiography before and after daclizumab treatment for patient 6. A and B, Late-phase fluorescein angiography frames of right and left eyes while patient is taking mycophenolate mofetil and cyclosporin A and immediately before starting daclizumab treatment. Note the temporal arcade vasculitis. C and D, After 2 years of daclizumab treatment, there is no vasculitis in the late frames of the angiogram.

Table. 
Clinical Data of Patients With Birdshot Chorioretinopathy Treated With Daclizumab
Clinical Data of Patients With Birdshot Chorioretinopathy Treated With Daclizumab
1.
Ryan  SJMaumenee  AE Birdshot retinochoroidopathy. Am J Ophthalmol 1980;89 (1) 31- 45
PubMed
2.
Kaplan  HJAaberg  TM Birdshot retinochoroidopathy. Am J Ophthalmol 1980;90 (6) 773- 782
PubMed
3.
Gass  JD Vitiliginous chorioretinitis. Arch Ophthalmol 1981;99 (10) 1778- 1787
PubMedArticle
4.
Fuerst  DJTessler  HHFishman  GA  et al.  Birdshot retinochoroidopathy. Arch Ophthalmol 1984;102 (2) 214- 219
PubMedArticle
5.
Priem  HAOosterhuis  JA Birdshot chorioretinopathy: clinical characteristics and evolution. Br J Ophthalmol 1988;72 (9) 646- 659
PubMedArticle
6.
Nussenblatt  RBMittal  KKRyan  S  et al.  Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol 1982;94 (2) 147- 158
PubMed
7.
Priem  HAKijlstra  ANoens  L  et al.  HLA typing in birdshot chorioretinopathy. Am J Ophthalmol 1988;105 (2) 182- 185
PubMed
8.
LeHoang  POzdemir  NBenhamou  A  et al.  HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol 1992;113 (1) 33- 35
PubMed
9.
Levinson  RDRajalingam  RPark  MS  et al.  Human leukocyte antigen A29 subtypes associated with birdshot retinochoroidopathy. Am J Ophthalmol 2004;138 (4) 631- 634
PubMedArticle
10.
Oh  KTChristmas  NJFolk  JC Birdshot retinochoroiditis: long term follow-up of a chronically progressive disease. Am J Ophthalmol 2002;133 (5) 622- 629
PubMedArticle
11.
Rothova  ABerendschot  TTProbst  K  et al.  Birdshot chorioretinopathy: long-term manifestations and visual prognosis. Ophthalmology 2004;111 (5) 954- 959
PubMedArticle
12.
Kiss  SAhmed  MLetko  EFoster  CS Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 2005;112 (6) 1066- 1071
PubMedArticle
13.
Thorne  JEJabs  DAPeters  GBHair  DDunn  JPKempen  JH Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol 2005;140 (1) 45- 51
PubMedArticle
14.
Becker  MDWertheim  MSSmith  JRRosenbaum  JT Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm 2005;13 (4) 289- 293
PubMedArticle
15.
Caspi  RRRoberge  FGMcAllister  CG  et al.  T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol 1986;136 (3) 928- 933
PubMed
16.
Okada  AASakai  JUsui  M  et al.  Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6 (2) 111- 120
PubMedArticle
17.
Guex-Crosier  YRaber  JChan  C-C  et al.  Humanized antibodies against the α-chain of the IL-2 receptor and against the β-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 1997;158 (1) 452- 458
PubMed
18.
Vincenti  FKirkman  RLight  S  et al.  Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338 (3) 161- 165
PubMedArticle
19.
Nussenblatt  RBFortin  ESchiffman  R  et al.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999;96 (13) 7462- 7466
PubMedArticle
20.
Papaliodis  GNChu  DFoster  CS Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003;110 (4) 786- 789
PubMedArticle
21.
Nussenblatt  RBPeterson  JSFoster  CS  et al.  Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis. Ophthalmology 2005;112 (5) 764- 770
PubMedArticle
22.
Li  ZLim  WKSankaranarayana  PM  et al.  Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56bright regulatory NK cells in patients with active uveitis. J Immunol 2005;174 (9) 5187- 5191
PubMedArticle
23.
Jobin  DThillaye  Bde Kozak  Y  et al.  Severe retinochoroidopathy: variations of humoral and cellular immunity to S-antigen in a longitudinal study. Curr Eye Res 1990;9 ((suppl)) 91- 96
PubMedArticle
24.
Boisgerault  FKhalil  ITieng  V  et al.  Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from retinal soluble antigen, a candidate autoantigen in birdshot retinopathy. Proc Natl Acad Sci U S A 1996;93 (8) 3466- 3470
PubMedArticle
25.
Levinson  RDBrezin  ARothova  AAccorinti  MHolland  GN Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol 2006;141 (1) 185- 187
PubMedArticle
26.
Harper  SLChorich  LJFoster  CS Diagnosis of uveitis. Foster  CSVitale  ATDiagnosis and Treatment of Uveitis. Philadelphia, PA WB Saunders Co2002;79- 103
27.
Marmor  MF An updated standard for clinical electroretinography. Arch Ophthalmol 1995;113 (11) 1375- 1376
PubMedArticle
28.
Jabs  DANussenblatt  RBRosenbaum  JTThe Standardization of Uveitis Nomenclature (SUN) Working Group, Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol 2005;140 (3) 509- 516
PubMedArticle
29.
Sobrin  LLam  BLLiu  M  et al.  Electroretinography monitoring in birdshot chorioretinopathy. Am J Ophthalmol 2005;140 (1) 52- 64
PubMedArticle
30.
Zacks  DNSamson  CMLoewenstein  J  et al.  Electroretinograms as an indicator of disease activity in birdshot retinochoroidopathy. Graefes Arch Clin Exp Ophthalmol 2002;240 (8) 601- 607
PubMedArticle
31.
Holder  GERobson  AGPavesio  CGraham  EM Electrophysiological characterisation and monitoring in the management of birdshot chorioretinopathy. Br J Ophthalmol 2005;89 (6) 709- 718
PubMedArticle
32.
Fishman  GAChappelow  AWAnderson  RJ  et al.  Short-term intervisit variability of ERG amplitudes in normal subjects and patients with retinitis pigmentosa. Retina 2005;25 (8) 1014- 1021
PubMedArticle
33.
Birch  DGAnderson  JL Standardized full-field electroretinography: normal values and their variation with age. Arch Ophthalmol 1992;110 (11) 1571- 1576
PubMedArticle
34.
Gordon  LKGoldhart  RHolland  GN  et al.  Standardized visual field assessment for patients with birdshot chorioretinopathy. Ocul Immunol Inflamm 2006;14 (6) 325- 332
PubMedArticle
35.
Nashan  BLight  SHardie  IR  et al.  Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation 1999;67 (1) 110- 115
PubMedArticle
36.
Webster  ACPlayford  EGHiggins  G  et al.  Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004;77 (2) 166- 176
PubMedArticle
37.
 Zenapax (daclizumab) [drug label].  Nutley, NJ Hoffman-LaRoche Laboratories Inc2005;
38.
Hershberger  REStarling  RCEisen  HJ Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352 (26) 2705- 2713
PubMedArticle
39.
Kobashigawa  JDavid  KMorris  J  et al.  Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc 2005;37 (2) 1333- 1339
PubMedArticle
40.
Petrikovits  EBedanova  HNecas  J  et al.  Daclizumab in the induction phase of immunosuppression in heart transplant recipients. Ann Transplant 2005;10 (3) 5- 10
PubMed
41.
Nussenblatt  RBThompson  DJSLi  Z  et al.  Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003;21 (3) 283- 293
PubMedArticle
Clinical Sciences
February 01, 2008

Daclizumab for Treatment of Birdshot Chorioretinopathy

Author Affiliations

Author Affiliations: Massachusetts Eye Research and Surgery Institute, Cambridge (Drs Sobrin, Huang, Kafkala, Choopong, and Foster); and Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Dr Christen).

Arch Ophthalmol. 2008;126(2):186-191. doi:10.1001/archophthalmol.2007.49
Abstract

Objective  To report the outcomes for daclizumab in the treatment of birdshot chorioretinopathy (BSCR) refractory to traditional immunomodulatory therapy (IMT).

Methods  We retrospectively reviewed medical records of 8 patients with BSCR whose disease was refractory to or who were intolerant of traditional IMT. All patients received 1 mg/kg of daclizumab intravenously at 2-week intervals initially at 1 referral uveitis practice. Main outcome measures were changes in visual acuity, vitreous inflammation, fluorescein angiographic pathologic features, electroretinography (ERG) parameters, concomitant IMT requirements, and adverse events.

Results  Over a mean follow-up of 25.6 months, 7 patients had either stabilization or improvement in visual acuity of both eyes and complete resolution of vitreous inflammation. Six patients had resolution of vasculitis on fluorescein angiography. The ERG 30-Hz implicit times and the bright scotopic amplitudes worsened in some patients despite abolition of clinically evident inflammation. Four patients were able to discontinue all other IMT and remain inflammation free while receiving only daclizumab treatment. Two patients developed adverse effects that led to daclizumab treatment discontinuation.

Conclusions  Daclizumab therapy was effective in stabilizing vision and decreasing inflammation in most patients with BSCR. The ERG parameters continued to decline in some patients despite adequate inflammatory control. Regular serologic monitoring is critical to detect adverse events.

Birdshot chorioretinopathy (BSCR) is a bilateral intraocular inflammatory disease characterized by vitritis and multiple cream-colored fundus lesions.15 It is highly associated with HLA-A29 haplotypy.69 The natural history of BSCR is one of progressive retinal dysfunction leading to poor vision.10,11 Intermittent treatment of inflammatory exacerbations does not meaningfully impact this adverse natural history.10,11 For this reason, prolonged systemic immunomodulatory therapy (IMT) has been recommended and has shown promise for preservation of retinal function and vision.1214 However, some patients continue to lose retinal function despite treatment with traditional IMT agents, such as cyclosporine and mycophenolate mofetil.11 The recent development of biologic agents that target inflammatory cytokines may be an alternative for these patients.

The IL-2 complex is a receptor system expressed on T-lymphocyte surface membranes after T-lymphocyte activation. It played a role in inflammation induction in an animal model of uveitis, and IL-2 itself was found at high levels in a similar model.15,16 Its blockade leads to decreased ocular inflammation.17 These findings form the rationale for anti–IL-2 receptor therapy in uveitis.

Daclizumab, a humanized IgG monoclonal antibody that binds CD25 of the human IL-2 receptor, is approved for prophylaxis of acute rejection in patients receiving renal transplants.18 It has been used off-label for uveitis with positive results in prospective studies with as much as 4 years of follow-up.1921 Its mechanism of action may be via induction of CD56bright cells, which may have a beneficial effect on the remission of active uveitis.22

The pathophysiology of BSCR remains unknown, but evidence suggests autoimmunity, with activated T-cell–mediated immunity directed against retinal S antigen and other retina-specific proteins.6,23,24 This is the rationale for use of daclizumab in BSCR specifically. In this report, we describe our experience with daclizumab treatment in patients with BSCR who did not tolerate traditional IMT or in whom IMT failed.

METHODS

The Human Studies Committee of the Massachusetts Eye and Ear Infirmary approved the retrospective review of data with waiver of informed consent. Cases were consecutive patients with BSCR refractory to traditional IMT who received daclizumab (Zenapax; Hoffman-LaRoche, Inc, Nutley, NJ) between January 1, 2001, and December 31, 2006, administered by one of the us (C.S.F.) at a tertiary referral center. All patients met the diagnostic criteria for BSCR determined at an international consensus conference.25 In our practice, a stepladder approach to IMT is used with patients with BSCR. Initially, either an antimetabolite alone or in combination with a signal transduction inhibitor, such as cyclosporine or sirolimus, is used. If patients are refractory to or intolerant of this therapy, other antimetabolites and signal transduction inhibitors are used until an effective, tolerable combination is found. Patients with BSCR were considered refractory to IMT if the clinical examination and ancillary test results demonstrated persistent inflammation while taking maximum doses of at least 2 immunosuppressive agents for at least 2 years of continuous therapy. Intolerance to medical therapy included any of the following adverse effects: significant gastrointestinal symptoms; pronounced fatigue; leukopenia; and clinically significant changes in liver function test (LFT) results, creatinine level, or blood pressure.

Daclizumab (1 mg/kg) was infused over 1 hour every 2 weeks initially. After suppression of inflammation was sustained over 3 infusions, the interval was increased by 1 week. This process was repeated until the longest effective interval was achieved. Before each infusion, a complete blood cell count and LFTs were done. At each follow-up visit, a thorough history was taken and examination performed. Vitreous cells were graded by means of previously described standardized grading criteria.26 Every 6 months, full-field electroretinography (ERG) was performed in accordance with a standard protocol.27 Fluorescein angiograms (FAs) were also obtained every 6 months. Retinal vasculitis was defined as retinovascular leakage on FA. Therapy failure occurred if subjective symptoms, visual acuity (VA), and/or signs of inflammation (vitreous cell, retinal vasculitis on FA) did not improve after 3 infusions. Intolerance of daclizumab requiring cessation of treatment was defined as stated earlier for other IMT.

The outcome measures were changes in Snellen VA, degree of vitreous cells, vascular leakage on FA, ERG parameters, and concomitant immunosuppressive requirements. Adverse events were also assessed. A Snellen VA change of 2 lines or more in either eye was considered a clinically significant change. Standardization of Uveitis Nomenclature Working Group criteria for improvement and worsening of inflammation were applied to our grading scale for vitreous cells.28 The 30-Hz flicker implicit times and bright scotopic amplitudes were 2 ERG indicators chosen because of their correlation with clinically relevant parameters such as VA and the ability to taper IMT.2931 A change in the implicit time by 2 milliseconds or more and a change in the amplitude by 25% or more were considered clinically significant.32 Results of FA were graded according to a previously described scale: 0 = no retinovascular leakage, 1 = large vessel leakage, 2 = small vessel leakage, 3 = cystoid macular edema, and 4 = retinal pigment epithelium atrophy in the posterior pole.29 A 1-step change on this scale was considered a clinically significant change. Concomitant IMT was tapered if the patient achieved control of inflammation. Any decrease in the number or dosage of IMT medications was recorded. Unexpected complaints and complications were recorded as adverse events.

RESULTS

Of the 34 patients with BSCR who received conventional IMT during the period of this study, 26 responded favorably while 8 patients were refractory to IMT and given daclizumab. The clinical data and outcomes for each patient are summarized in the Table. The mean patient age was 50 years with a range of 42 to 61 years. All patients were HLA-A29–positive women. The indications for switching to daclizumab treatment were ongoing inflammation despite maximal medical therapy in 6 patients and IMT intolerance in 2 patients. Patient 2 had pronounced fatigue with 2 different signal transduction inhibitors and previous monotherapy with antimetabolites had failed. Patient 5 had persistent leukopenia with conventional IMT regimens. All patients had retinal vasculitis on FA at daclizumab treatment initiation, and all patients except patient 2 had vitreous cells at the onset. The mean number of daclizumab infusions was 27.6, with a range of 16 to 49, and the mean follow-up time from the first infusion was 25.6 months, with a range of 12 to 55 months. The medications listed in the Table reflect the IMT regimen immediately prior to the initiation of daclizumab treatment.

All 8 patients achieved initial control of vitreous inflammation with the addition of daclizumab treatment, and 7 patients had control of vitreous inflammation over the entire follow-up period. After achieving suppression of ocular inflammation, we were able to reduce either the dosage of a particular IMT or the number of IMTs for 2 patients (patients 2 and 3). Four patients (patients 1, 5, 6, and 8) were able to discontinue all other IMT while receiving only daclizumab treatment.

One patient (patient 4) had recurrent vitreous inflammation and unilateral vision loss. After 11 months of inflammation suppression while taking daclizumab, she had an increase in vitreous inflammation requiring concurrent intravenous methylprednisolone infusions for 2 cycles. Her VA decreased from 20/50 OS to 20/200 OS within 9 months of starting daclizumab treatment, secondary to progression of preexisting subfoveal choroidal neovascularization treated with various modalities, including photodynamic therapy, intravitreal bevacizumab administration, and intravitreal triamcinolone acetonide administration. In addition, patient 7 lost vision in her right eye within 3 months of starting daclizumab treatment because of progression of a preexisting posterior subcapsular cataract. She underwent cataract surgery, and 1 month postoperatively, she recovered vision back to the level she had at daclizumab treatment initiation. The cataract progression was not thought to be related to daclizumab treatment as it was unilateral and occurred early in the daclizumab treatment; in addition, no other patient had cataract progression during the follow-up period.

When compared with pre–daclizumab treatment values, 30-Hz flicker implicit times at 6 months after therapy initiation were prolonged by 2 milliseconds or more in 5 eyes (right eye of patient 1, left eyes of patients 3 and 7, and both eyes of patient 4). At 6 months, only the 2 eyes from patient 8 showed a shortening of their implicit times. When comparing the pre–daclizumab treatment ERG with the last available ERG for each patient, the 30-Hz implicit times were more prolonged in 4 eyes. This prolongation was found not only in the patient who had uncontrolled vitreous inflammation (patient 4) but also in 1 eye of each of 2 patients who had inflammation control.

After 6 months of daclizumab treatment, the bright scotopic amplitudes decreased by at least 25% in 3 eyes, increased by at least 25% in 3 eyes, and remained stable in the rest. Over the follow-up period, 2 eyes demonstrated a decrease in the bright scotopic amplitude by 25% or more. This included the 1 eye of patient 4, who had clinical control of inflammation. Six eyes of 4 patients (patients 1 and 6-8) showed an increase in bright scotopic amplitudes by 25% or more. Changes in dim scotopic (isolated rod) b-wave amplitudes mirrored the changes of the bright scotopic amplitudes.

The Figure shows a representative patient with large-vessel retinal vasculitis that resolved with daclizumab treatment. Over the full follow-up period, the grade of FA pathologic features was improved or stable in all but 2 eyes. One was patient 4 who developed scarring secondary to her choroidal neovascular membrane. The other was patient 8 who had persistent perifoveal small-vessel leakage in her right eye despite resolution of vitritis and vision stability.

Two patients developed adverse events that prompted discontinuation of daclizumab treatment. Patient 4 had a rise in alanine aminotransferase (ALT) level to 244 U/L (to convert to microkatals per liter, multiply by 0.0167) and aspartate aminotransferase (AST) level to 149 U/L (to convert to microkatals per liter, multiply by 0.0167) (upper limits of normal in our laboratory are 40 U/L and 30 U/L, respectively) in her 14th month of daclizumab treatment. The medication was stopped and a comprehensive workup for hepatitis was performed. The enzymes normalized to an ALT level of 27 U/L and an AST level of 25 U/L; no other cause of liver toxic reaction was discovered. Daclizumab treatment was restarted at two-thirds of her usual dose to control recurrent inflammation. The LFT levels rose once again (ALT, 112 U/L and ALT, 57 U/L) after 1 infusion and the medication was stopped. This patient also had transient LFT level elevation while taking a sirolimus and mycophenolate mofetil combination. Patient 7's white blood cell count decreased to 2000 cells/μL (to convert to × 109/L, multiply by 0.001) during her third year of daclizumab treatment (lower limit of normal in our laboratory is 3800 cells/μL). After the medication was stopped, her white blood cell count recovered slowly over 7 months to 3500 cells/μL. She did not have any infections during the period of leukopenia. She has remained inflammation free not taking any medication during this interval. This patient also had transient leukopenia while taking mycophenolate mofetil once. One patient developed a less serious adverse event, transient diarrhea, after 1 infusion, which did not recur.

COMMENT

We report the successful use of daclizumab treatment in patients with BSCR resistant to traditional IMT with initial inflammation control in all 8 patients. To our best knowledge, this is the first series exclusively examining daclizumab treatment in BSCR. There are 2 prior reports that include daclizumab-treated patients with BSCR. One study of subcutaneous daclizumab treatment for uveitis included 1 patient with BSCR, and 1 series on long-term outcomes of IMT for BSCR by our group included 2 patients who are also included in this series.12,21 The current report describes patients who have tolerated up to 49 infusions (to our knowledge, the largest number reported to date for BSCR) with adequate inflammatory control. This suggests that daclizumab treatment may be efficacious for inflammation control in patients who need such therapy over a protracted period.

Six patients in this study had inflammation that was refractory to mycophenolate mofetil treatment combined with either cyclosporine or sirolimus but then responded to daclizumab treatment. The reasons for response to daclizumab treatment following nonresponse to traditional IMT are unclear. Mycophenolate mofetil inhibits T- and B-lymphocyte proliferation by blocking production of nucleotides required for DNA synthesis but has no effect on cytokine production associated with early T-cell signaling transduction. Thus, it may be less effective for preexisting, ongoing inflammation than daclizumab. Cyclosporine inhibits IL-2 production and T-cell stimulation by blocking calcineurin, a phosphatase-required IL-2 gene transcriptional activation. Again, previously activated T cells may not be suppressed as well with cyclosporine as with daclizumab. Sirolimus binds intracellular protein kinases, thereby interrupting IL-2 receptor signal and blocking T-cell proliferation in response to IL-2. It works downstream from daclizumab and should inhibit ongoing inflammation to a similar degree. Intravenous delivery of daclizumab and superior ocular penetration may be partly responsible for its increased effectiveness.

Despite the positive effects on visual stabilization, intraocular inflammation, and vasculitis, some patients experienced deterioration in ERG 30-Hz implicit times and bright scotopic amplitudes. This is troubling because it indicates continued retinal function loss in a subset of patients despite other indicators of controlled inflammation. Many patients' implicit times were prolonged beyond the normal range (25-32 milliseconds) prior to starting daclizumab treatment. While ERG values decline with age, this effect alone is insufficient to explain the worsening seen over the follow-up period.33 There are no reports examining retinal toxic reaction caused by daclizumab treatment and no reports in the rheumatologic or transplantation literature to suggest ocular toxic reaction caused by daclizumab treatment. This divergence between traditional outcome measures of success (preservation of vision and inflammation control) and ERG parameters in some patients suggests that the traditional measures may not be the best ones for monitoring this disease process with its tendency for subclinical, insidious progression in many patients.

Daclizumab treatment was associated with stability or improvement of both ERG parameters in 3 eyes that had treatment for more than 2 years (patient 6, both eyes and patient 7, left eye). To our knowledge, there is no documentation of sustained stability or improvement of ERG parameters for longer than 2 years with traditional IMT. There are some reports of ERG parameter improvement over approximately 1-year periods in patients treated with steroid-sparing IMT, including cyclosporine.29,31 Patients treated with steroids alone show progressive ERG decline.10 Serial visual field tests are another potentially useful ancillary test for following up BSCR.34 However, we did not perform serial visual field tests as part of this study.

Six patients in this study continue to receive daclizumab treatment on a regular basis. The appropriate length of treatment is unclear and may be indefinite. We have found that most patients begin to complain of symptoms of floaters and blurred vision prior to their next infusion once the infusions are extended beyond every 6 weeks, and we have been able to prolong the interval successfully to greater than 6 weeks in only 1 patient. The stable VA and sustained vitreous inflammation control in patient 7, who stopped treatment, indicates therapy could be finite in some cases; we do not yet know how to identify which patients this will be true for. Thus, we have not established any criteria for stopping daclizumab treatment for patients who are responding well to the medication. Currently, our only criteria for withdrawing daclizumab are intolerance and/or lack of response.

In the United States, where daclizumab is used off-label for uveitis, it is challenging to convince third-party payers to cover the expense of daclizumab treatment. The cost can vary but is approximately $1000 per infusion. Payment approval invariably involves hours of telephone conversations and written correspondence explaining the need for treatment. Despite these obstacles, we were able to obtain third-party payer coverage of daclizumab treatment for all the patients who were considered for the drug.

Elevated LFT levels and leukopenia were the 2 adverse events necessitating therapy discontinuation. Because both patients had experienced the same adverse effects with previous IMT, it may be that their liver and bone marrow, respectively, were particularly susceptible. Regardless, these findings underscore the need for regular monitoring during therapy.

The number of patients in this study is too small to form conclusions about daclizumab safety in patients with BSCR. The daclizumab adverse effect profile in patients with renal allograft has been widely studied and does not differ from that of placebo except for an increased risk of cellulitis and wound infections.18,3537 There have been no reports of increased malignancy risk or mortality in long-term studies.37 In the field of cardiac transplantation, 1 randomized, placebo-controlled study for rejection prophylaxis showed increased mortality in patients receiving daclizumab at 6 and 12 months.38 Some of the increase in mortality appeared related to a higher incidence of severe infections and concomitant use of anti–lymphocyte antibody therapy. Other cardiac transplantation studies have failed to show an increased risk of mortality or infection.39,40 In uveitis studies, daclizumab treatment has not been associated with serious infection or death.1921,41 The most common adverse effects reported are skin rashes, mild peripheral edema, and lymphadenopathy. There is 1 report of a patient with uveitis treated with daclizumab for 4 years who developed a malignancy that was curatively resected; the cancer was not clearly related to therapy.41

All of the patients in this study were women. While BSCR has been found by some to be more common in women,3 our sample appears unusual and may indicate that BSCR in women is more resistant to conventional IMT. Alternatively, there may be a selection bias for women in our study that was not readily apparent to us. We recently began to treat our ninth patient with BSCR, a man, with daclizumab.

Daclizumab treatment was efficacious in controlling inflammation and stabilizing vision for the majority of patients with BSCR in this study. However, some patients' ERG parameters continued to worsen despite these positive indicators. Patients' blood cell counts and LFT levels must be monitored closely to detect leukopenia or toxic hepatitis and discontinue therapy promptly, even if the patient has tolerated the therapy well for a year or more. This study's results must be interpreted in the context of the retrospective design, lack of a control group, relatively small number of patients, and limited follow-up for some patients. Larger studies are needed to definitively answer questions of safety and efficacy. In particular, prospective, controlled, long-term trials to explore continued ERG decline in some patients despite inflammation suppression are necessary in the ongoing search for treatments that can halt progressive retinal dysfunction in BSCR.

Back to top
Article Information

Correspondence: C. Stephen Foster, MD, Massachusetts Eye Research and Surgery Institute, 5 Cambridge Center, Eighth Floor, Cambridge, MA 02142 (sfoster@mersi.us).

Submitted for Publication: April 29, 2007; final revision received July 8, 2007; accepted July 22, 2007.

Author Contributions: Dr Foster had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Financial Disclosure: None reported.

References
1.
Ryan  SJMaumenee  AE Birdshot retinochoroidopathy. Am J Ophthalmol 1980;89 (1) 31- 45
PubMed
2.
Kaplan  HJAaberg  TM Birdshot retinochoroidopathy. Am J Ophthalmol 1980;90 (6) 773- 782
PubMed
3.
Gass  JD Vitiliginous chorioretinitis. Arch Ophthalmol 1981;99 (10) 1778- 1787
PubMedArticle
4.
Fuerst  DJTessler  HHFishman  GA  et al.  Birdshot retinochoroidopathy. Arch Ophthalmol 1984;102 (2) 214- 219
PubMedArticle
5.
Priem  HAOosterhuis  JA Birdshot chorioretinopathy: clinical characteristics and evolution. Br J Ophthalmol 1988;72 (9) 646- 659
PubMedArticle
6.
Nussenblatt  RBMittal  KKRyan  S  et al.  Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol 1982;94 (2) 147- 158
PubMed
7.
Priem  HAKijlstra  ANoens  L  et al.  HLA typing in birdshot chorioretinopathy. Am J Ophthalmol 1988;105 (2) 182- 185
PubMed
8.
LeHoang  POzdemir  NBenhamou  A  et al.  HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol 1992;113 (1) 33- 35
PubMed
9.
Levinson  RDRajalingam  RPark  MS  et al.  Human leukocyte antigen A29 subtypes associated with birdshot retinochoroidopathy. Am J Ophthalmol 2004;138 (4) 631- 634
PubMedArticle
10.
Oh  KTChristmas  NJFolk  JC Birdshot retinochoroiditis: long term follow-up of a chronically progressive disease. Am J Ophthalmol 2002;133 (5) 622- 629
PubMedArticle
11.
Rothova  ABerendschot  TTProbst  K  et al.  Birdshot chorioretinopathy: long-term manifestations and visual prognosis. Ophthalmology 2004;111 (5) 954- 959
PubMedArticle
12.
Kiss  SAhmed  MLetko  EFoster  CS Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 2005;112 (6) 1066- 1071
PubMedArticle
13.
Thorne  JEJabs  DAPeters  GBHair  DDunn  JPKempen  JH Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol 2005;140 (1) 45- 51
PubMedArticle
14.
Becker  MDWertheim  MSSmith  JRRosenbaum  JT Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm 2005;13 (4) 289- 293
PubMedArticle
15.
Caspi  RRRoberge  FGMcAllister  CG  et al.  T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol 1986;136 (3) 928- 933
PubMed
16.
Okada  AASakai  JUsui  M  et al.  Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6 (2) 111- 120
PubMedArticle
17.
Guex-Crosier  YRaber  JChan  C-C  et al.  Humanized antibodies against the α-chain of the IL-2 receptor and against the β-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 1997;158 (1) 452- 458
PubMed
18.
Vincenti  FKirkman  RLight  S  et al.  Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338 (3) 161- 165
PubMedArticle
19.
Nussenblatt  RBFortin  ESchiffman  R  et al.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999;96 (13) 7462- 7466
PubMedArticle
20.
Papaliodis  GNChu  DFoster  CS Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003;110 (4) 786- 789
PubMedArticle
21.
Nussenblatt  RBPeterson  JSFoster  CS  et al.  Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis. Ophthalmology 2005;112 (5) 764- 770
PubMedArticle
22.
Li  ZLim  WKSankaranarayana  PM  et al.  Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56bright regulatory NK cells in patients with active uveitis. J Immunol 2005;174 (9) 5187- 5191
PubMedArticle
23.
Jobin  DThillaye  Bde Kozak  Y  et al.  Severe retinochoroidopathy: variations of humoral and cellular immunity to S-antigen in a longitudinal study. Curr Eye Res 1990;9 ((suppl)) 91- 96
PubMedArticle
24.
Boisgerault  FKhalil  ITieng  V  et al.  Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from retinal soluble antigen, a candidate autoantigen in birdshot retinopathy. Proc Natl Acad Sci U S A 1996;93 (8) 3466- 3470
PubMedArticle
25.
Levinson  RDBrezin  ARothova  AAccorinti  MHolland  GN Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol 2006;141 (1) 185- 187
PubMedArticle
26.
Harper  SLChorich  LJFoster  CS Diagnosis of uveitis. Foster  CSVitale  ATDiagnosis and Treatment of Uveitis. Philadelphia, PA WB Saunders Co2002;79- 103
27.
Marmor  MF An updated standard for clinical electroretinography. Arch Ophthalmol 1995;113 (11) 1375- 1376
PubMedArticle
28.
Jabs  DANussenblatt  RBRosenbaum  JTThe Standardization of Uveitis Nomenclature (SUN) Working Group, Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol 2005;140 (3) 509- 516
PubMedArticle
29.
Sobrin  LLam  BLLiu  M  et al.  Electroretinography monitoring in birdshot chorioretinopathy. Am J Ophthalmol 2005;140 (1) 52- 64
PubMedArticle
30.
Zacks  DNSamson  CMLoewenstein  J  et al.  Electroretinograms as an indicator of disease activity in birdshot retinochoroidopathy. Graefes Arch Clin Exp Ophthalmol 2002;240 (8) 601- 607
PubMedArticle
31.
Holder  GERobson  AGPavesio  CGraham  EM Electrophysiological characterisation and monitoring in the management of birdshot chorioretinopathy. Br J Ophthalmol 2005;89 (6) 709- 718
PubMedArticle
32.
Fishman  GAChappelow  AWAnderson  RJ  et al.  Short-term intervisit variability of ERG amplitudes in normal subjects and patients with retinitis pigmentosa. Retina 2005;25 (8) 1014- 1021
PubMedArticle
33.
Birch  DGAnderson  JL Standardized full-field electroretinography: normal values and their variation with age. Arch Ophthalmol 1992;110 (11) 1571- 1576
PubMedArticle
34.
Gordon  LKGoldhart  RHolland  GN  et al.  Standardized visual field assessment for patients with birdshot chorioretinopathy. Ocul Immunol Inflamm 2006;14 (6) 325- 332
PubMedArticle
35.
Nashan  BLight  SHardie  IR  et al.  Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation 1999;67 (1) 110- 115
PubMedArticle
36.
Webster  ACPlayford  EGHiggins  G  et al.  Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004;77 (2) 166- 176
PubMedArticle
37.
 Zenapax (daclizumab) [drug label].  Nutley, NJ Hoffman-LaRoche Laboratories Inc2005;
38.
Hershberger  REStarling  RCEisen  HJ Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352 (26) 2705- 2713
PubMedArticle
39.
Kobashigawa  JDavid  KMorris  J  et al.  Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc 2005;37 (2) 1333- 1339
PubMedArticle
40.
Petrikovits  EBedanova  HNecas  J  et al.  Daclizumab in the induction phase of immunosuppression in heart transplant recipients. Ann Transplant 2005;10 (3) 5- 10
PubMed
41.
Nussenblatt  RBThompson  DJSLi  Z  et al.  Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003;21 (3) 283- 293
PubMedArticle
×